Clinical Trial Search

Primary: Change From Baseline in HbA1c (Glycosylated Haemoglobin) — -0.45; -0.50; -0.54; -0.34 percentage of glycosylated haemoglobin

Primary: Adjusted Mean Change in HbA1c From Baseline to Week 24 — 0.03; -0.87 percentage of hemoglobin — p=<0.0001

Primary: Percentage of Participants With Lowering of Overall Target Plaque Severity Score (OTPSS) at Day 84 — 53.3; 30.0 percentage of participants — p=0.23

Primary: Absolute Change in Lesion Counts (Total, Inflammatory, and Non-inflammatory) From Baseline to Week 12 — -16.8; -18.1; -18.9; -18.8 Lesion count — p=0.692

Primary: Nutritional Quality of Food Purchases — 37.62; 41.12; 39.66; 41.01 Average NUVAL Score

Primary: Change From Baseline in Schiff Sensitivity Score of Experimental Oral Rinses 1 and 2 Against a Placebo Oral Rinse at Week 8 — 2.53; 2.55; 2.55; -1.19 score on a scale…

Primary: HbA1c Change From Baseline After 24 Weeks Double-blind Randomized Treatment — -0.03; -0.63 Percentage of HbA1c — p=<0.0001

Primary: Maximum Change in Mean Mouth and Throat Soreness (MTS) Score From Baseline Through Weeks of Radiation Therapy Using the MTS Question of the Modified Oral Mucositis Daily…

Primary: Number of Participants With Acute Kidney Injury — 64; 60 Participants — p=.75

Primary: Exploratory: Levels of IL-6/sIL-6R Complex — NA pg/mL

Primary: Percentage of Participants Achieving Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) 50 at Month 12 — 78.9 percentage of participants

Primary: Remission of Vasculitis — 95 Percentage of participants

Primary: Serum Vitamin D — 75.13 mmol/L

Primary: Hierarchical Composite of Stroke, Myocardial Infarction, and Death — 8 Participants

Primary: Antitumor Activity of SB-715992 Using Objective Response Rates (Partial and Complete Responses) — 0 participants